Table 4.
Cause-Specific SMRs and 95% CIs, Excluding Deaths Due to Recurrence
| Parameter | Subsequent Malignancy |
Cardiac |
Pulmonary |
Other Causes |
External Causes |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SMR | No. of Deaths | 95% CI | SMR | No. of Deaths | 95% CI | SMR | No. of Deaths | 95% CI | SMR | No. of Deaths | 95% CI | SMR | No. of Deaths | 95% CI | |
| All patients | 15.2 | 470 | 13.9 to 16.6* | 7.0 | 142 | 5.9 to 8.2* | 8.8 | 67 | 6.8 to 11.2* | 2.6 | 200 | 2.3 to 3.0* | 0.9 | 186 | 0.8 to 1.1 |
| Sex‡ | |||||||||||||||
| Male | 14.2 | 242 | 12.4 to 16.1* | 6.2 | 89 | 5.0 to 7.6* | 8.5 | 39 | 6.1 to 11.7* | 2.1 | 107 | 1.7 to 2.5* | 0.9 | 152 | 0.8 to 1.1 |
| Female | 16.4 | 228 | 14.4 to 18.7* | 8.9 | 53 | 6.6 to 11.6* | 9.2 | 28 | 6.1 to 13.2* | 3.8 | 93 | 3.1 to 4.7* | 0.9 | 34 | 0.6 to 1.2 |
| Diagnosis | |||||||||||||||
| Acute lymphoblastic leukemia | 14.7 | 89 | 11.8 to 18.1* | 4.2 | 15 | 2.3 to 6.9* | 4.2 | 7 | 1.7 to 8.6* | 2.5 | 37 | 1.8 to 3.4* | 0.7 | 35 | 0.5 to 1.0† |
| Acute myeloid leukemia | 11.1 | 7 | 4.4 to 22.9* | 5.0 | 2 | 0.6 to 18.1 | 24.9 | 4 | 6.7 to 63.8* | 3.2 | 5 | 1.0 to 7.4† | 1.9 | 8 | 0.8 to 3.8 |
| Other leukemia | 19.0 | 11 | 9.5 to 33.9* | 5.4 | 2 | 0.6 to 19.4 | 32.6 | 5 | 10.5 to 76.1* | 0.7 | 1 | 0.0 to 3.8 | 0.4 | 2 | 0.1 to 1.6 |
| Astrocytomas | 12.4 | 31 | 8.4 to 17.6* | 6.2 | 10 | 3.0 to 11.4* | 20.7 | 13 | 11.0 to 35.4* | 4.0 | 25 | 2.6 to 6.0* | 1.1 | 19 | 0.7 to 1.7 |
| Medulloblastoma, PNET | 23.4 | 13 | 12.4 to 40.0* | 0.0 | 0 | 0.0 to 10.8 | 6.6 | 1 | 0.1 to 36.7 | 2.1 | 3 | 0.4 to 6.2 | 0.6 | 3 | 0.1 to 1.9 |
| Other CNS tumors | 11.4 | 7 | 4.6 to 23.5* | 0.0 | 0 | 0.0 to 8.6 | 12.8 | 2 | 1.4 to 46.3† | 4.9 | 8 | 2.1 to 9.7* | 2.1 | 9 | 1.0 to 4.0 |
| Hodgkin's disease | 20.0 | 149 | 16.9 to 23.5* | 11.9 | 62 | 9.1 to 15.3* | 10.8 | 17 | 6.3 to 17.2* | 2.6 | 46 | 1.9 to 3.5* | 1.0 | 33 | 0.7 to 1.4 |
| Non-Hodgkin's lymphoma | 14.0 | 37 | 9.8 to 19.3* | 6.5 | 13 | 3.5 to 11.1* | 9.1 | 6 | 3.3 to 19.7* | 2.1 | 15 | 1.2 to 3.4† | 1.0 | 19 | 0.6 to 1.5 |
| Kidney tumors | 16.4 | 27 | 10.8 to 23.8* | 12.7 | 11 | 6.3 to 22.8* | 4.2 | 2 | 0.5 to 15.1 | 3.1 | 12 | 1.6 to 5.5* | 0.8 | 11 | 0.4 to 1.4 |
| Neuroblastoma | 10.9 | 13 | 5.8 to 18.7* | 5.0 | 3 | 1.0 to 14.6† | 11.4 | 4 | 3.1 to 29.3* | 2.2 | 6 | 0.8 to 4.8 | 1.1 | 11 | 0.5 to 1.9 |
| Soft tissue sarcoma | 13.8 | 46 | 10.1 to 18.4* | 4.0 | 9 | 1.8 to 7.6* | 3.8 | 3 | 0.8 to 11.1 | 2.8 | 23 | 1.8 to 4.2* | 0.8 | 16 | 0.5 to 1.3 |
| Ewings sarcoma | 20.0 | 19 | 12.0 to 31.3* | 12.0 | 8 | 5.2 to 23.6* | 4.4 | 1 | 0.1 to 24.3 | 4.0 | 10 | 1.9 to 7.3* | 0.9 | 5 | 0.3 to 2.0 |
| Osteosarcoma | 8.1 | 20 | 4.9 to 12.4* | 3.9 | 7 | 1.6 to 8.1* | 3.6 | 2 | 0.4 to 12.9 | 1.4 | 9 | 0.6 to 2.7 | 1.1 | 14 | 0.6 to 1.9 |
| Other bone tumors | 3.4 | 1 | 0.0 to 18.9 | 0.0 | 0 | 0.0 to 16.8 | 0.0 | 0 | 0.0 to 60.0 | 0.0 | 0 | 0.0 to 5.3 | 0.9 | 1 | 0.0 to 4.8 |
NOTE. Subsequent malignancy reflects a new neoplasm. Cancer deaths resulting from progression of the original cancer are not included in the observed number of events. Other causes include deaths not due to recurrence, subsequent malignancy, cardiac, pulmonary, or external causes. External causes include non-medical deaths (ie, accidents, homicides, and suicides).
Abbreviations: SMR, standardized mortality ratio; PNET, primitive neuroectodermal tumor.
*
P < .01 for SMR.
†
P < .05 for SMR.